Journal Watch · Journal of Medicinal Chemistry · 2026
Designer Podophyllotoxin Derivatives with Significantly Improved Safety by Targeting LAT1 for the Treatment of Esophageal Cancer.
Mechanistic studies indicated that <b>B11</b> could accumulate in tumor cells in a LAT1-dependent manner and exert its antitumor effects by cytoskeleton disruption.
TL;DR
Mechanistic studies indicated that <b>B11</b> could accumulate in tumor cells in a LAT1-dependent manner and exert its antitumor effects by cytoskeleton disruption.
Key findings
- Pharmacokinetic experiments revealed that <b>B11</b> can achieve a higher drug distribution in tumors and minimize drug concentration in vital organs.
- Mechanistic studies indicated that <b>B11</b> could accumulate in tumor cells in a LAT1-dependent manner and exert its antitumor effects by cytoskeleton disruption.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Among the new analogs, <b>B11</b> as a LAT1-targeted amino acid conjugate, exhibited significantly greater anticancer activity against Eca109 cells than etoposide and with an ideal druggability profile. <b>B11</b> achieved a 64.6% TGI versus 30.6% for etoposide in mice bearing Eca109 xenografts in a single drug treatment. The MTD studies showed a more than 4-fold improvement for <b>B11</b> in animal tolerability compared to etoposide.
Full abstract (original)
Background: The severe toxicity of podophyllotoxin and its analogs primarily constrains their clinical application. We designed and synthesized a series of novel podophyllotoxin derivatives that target tumor-specific transporters to enhance tumor selectivity and reduce systemic toxicity.
What they did: Among the new analogs, <b>B11</b> as a LAT1-targeted amino acid conjugate, exhibited significantly greater anticancer activity against Eca109 cells than etoposide and with an ideal druggability profile. <b>B11</b> achieved a 64.6% TGI versus 30.6% for etoposide in mice bearing Eca109 xenografts in a single drug treatment. The MTD studies showed a more than 4-fold improvement for <b>B11</b> in animal tolerability compared to etoposide.
Results & conclusions: Pharmacokinetic experiments revealed that <b>B11</b> can achieve a higher drug distribution in tumors and minimize drug concentration in vital organs. Mechanistic studies indicated that <b>B11</b> could accumulate in tumor cells in a LAT1-dependent manner and exert its antitumor effects by cytoskeleton disruption.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.5c03829 · PubMed 41978912.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Journal of Medicinal Chemistry for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Mechanistic studies indicated that <b>B11</b> could accumulate in tumor cells in a LAT1-dependent manner and exert its antitumor effects by cytoskeleton disruption.
What type of study is this?
It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. Among the new analogs, <b>B11</b> as a LAT1-targeted amino acid conjugate, exhibited significantly greater anticancer activity against Eca109 cells than etoposide and with an ideal druggability profile.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.5c03829. PubMed ID: 41978912. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/designer-podophyllotoxin-derivatives-with-significantly-improved-safety-c03829/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides